所有图片(1)
Cis-[trans-1,2-cyclobutanebis(methylamine)-N,N′]-[(2S)-lactate-O1,O2)-platinum (II), D 19466, D-19466, D19466, [rel-(1R,2R)-1,2-cyclobutanedimethanamine-κN,kN′][(2S)-2-(hydroxy-kO)propanoato(2-)-kO]-, (SP-4-3)-platinum, trans-1,2-Cyclobutanedimethanamine, platinum complex
C9H18N2O3Pt
推荐产品
质量水平
检测方案
≥98% (NMR)
形式
powder
颜色
white to beige
溶解性
H2O: 2 mg/mL, clear (Warmed)
储存温度
−20°C
SMILES字符串
O=C1[O-][Pt+2]2(N[CH2]C3CCC3CN2)[O-]C1C
InChI
1S/C6H12N2.C3H5O3.Pt/c7-3-5-1-2-6(5)4-8;1-2(4)3(5)6;/h5-8H,1-4H2;2H,1H3,(H,5,6);/q-2;-1;+4/p-1/t;2-;/m.0./s1
InChI key
HADHSETVEMCBPU-TYOUJGAFSA-M
生化/生理作用
Lobaplatin (D-19466) is a third-generation platinum anticancer agent in vitro and in vivo, consisting of ~50:50 mixture of the two trans-1,2-cyclobutanedimethanamine diastereomers in complex with L-lactic acid. Llobaplatin shows antitumor efficacy against various human cancer cancer xenografts and significantly prolongs the survival of mice bearing P388 leukemia (mean life span increase post single i.p. in mg/kg = 46%/4.64 & 77/14.7). Compared to first and second generation platinum compounds, lobaplatin appears to be more stable, less toxic, have a better therapeutic index and may overcome tumor resistance.
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 108, 486-491 (2018-09-23)
Peritoneal metastasis from colorectal cancer (CRC) is related to poor prognosis. Intraperitoneal chemotherapy is an efficient method to treat peritoneal metastasis (PM); however, the outcomes remain unsatisfactory. The present study aimed to investigate the antitumor activity of lobaplatin and its
Cell death & disease, 10(10), 744-744 (2019-10-05)
We investigated the mechanism underlying the effect of a combination treatment of 125I radioactive seed implantation and lobaplatin (LBP) in hepatocellular carcinoma. The effects of administration of HCC cells and subcutaneous tumor model of mice with different doses of 125I
Cancer chemotherapy and pharmacology, 33(1), 43-47 (1993-01-01)
Lobaplatin [1,2-diamminomethylcyclobutane-platinum(II) lactate] is a new platinum compound with interesting preclinical activity and apparently no nephro- or neurotoxicity that is currently undergoing clinical phase II studies. Little is known about the cross-resistance between cisplatin and lobaplatin. The activity of this
Journal of cancer research and clinical oncology, 116(5), 439-442 (1990-01-01)
D-19466, a new platinum complex, was characterized. It showed no nephrotoxic side-effects as determined by the measurement of blood urea. It was cytotoxic in vitro for tumor cells in concentrations comparable to or lower than cytotoxic concentrations of cisplatin. It
Frontiers in oncology, 9, 538-538 (2019-08-21)
Platinum-based chemotherapy is recommended as the first-line treatment regimen for patients with advanced non-small-cell lung cancer (NSCLC). Lobaplatin (LBP), a third-generation platinum anti-neoplastic agent, has shown an improved efficacy. This study is aimed to investigate the mechanisms of LBP-induced apoptosis
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门